Research Article
IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment
Figure 5
Correlation between the anti-AG Ab level and clinical parameters. (a) The anti-Adi Ab level vs. viral load in HCV-1b carriers in stages F0–1. (b) The anti-Adi Ab level vs. the anti-HCV Ab level. (c) The anti-GA2 Ab level vs. the anti-HCV Ab level. (d) The anti-Gb5tri Ab level vs. the ALP level in stages F1–4.
(a) |
(b) |
(c) |
(d) |